[go: up one dir, main page]

SV2002000227A - 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida caso 20502 - Google Patents

2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida caso 20502

Info

Publication number
SV2002000227A
SV2002000227A SV2000000227A SV2000000227A SV2002000227A SV 2002000227 A SV2002000227 A SV 2002000227A SV 2000000227 A SV2000000227 A SV 2000000227A SV 2000000227 A SV2000000227 A SV 2000000227A SV 2002000227 A SV2002000227 A SV 2002000227A
Authority
SV
El Salvador
Prior art keywords
morfolin
piridin
bis
phenyl
isobutiramida
Prior art date
Application number
SV2000000227A
Other languages
English (en)
Inventor
Theresa Maria Ballard
Guy Andrew Higgins
Torsten Hoffmann
Sonia Maria Poli
Andrew Sleight
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SV2002000227A publication Critical patent/SV2002000227A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

EL INVENTO SE REFIERE AL COMPUESTO DE LA FORMULA I, QUE ES LA 2-(3, 5-BIS- TRIFUOROMETIL- FENIL)-N-METIL-N-(6- MORFOLIN-4-IL-4-O-TILIL-PIRIDIN-3-IL)-ISOBUTIRAMIDA. SE HA ENCONTRADO QUE ESTE COMPUESTO TIENE UNA ALTA AFINIDAD AL RECEPTOR NK-1 Y ES POR TANTO UTIL EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON ESTE RECEPTOR
SV2000000227A 1999-11-29 2000-11-28 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida caso 20502 SV2002000227A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
SV2002000227A true SV2002000227A (es) 2002-02-05

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000227A SV2002000227A (es) 1999-11-29 2000-11-28 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida caso 20502

Country Status (49)

Country Link
EP (1) EP1103545B1 (es)
JP (1) JP3480835B2 (es)
KR (1) KR100390117B1 (es)
CN (1) CN1152016C (es)
AR (1) AR033659A1 (es)
AT (1) ATE253561T1 (es)
AU (1) AU775292B2 (es)
BG (1) BG64622B1 (es)
BR (1) BRPI0005616B8 (es)
CA (1) CA2326529C (es)
CO (1) CO5251405A1 (es)
CZ (1) CZ299286B6 (es)
DE (2) DE60006340T2 (es)
DK (1) DK1103545T3 (es)
DO (1) DOP2000000106A (es)
EA (1) EA004404B1 (es)
ES (2) ES2208205T3 (es)
FR (1) FR2801590A1 (es)
GB (1) GB2356863A (es)
GC (1) GC0000151A (es)
GE (1) GEP20022763B (es)
GT (1) GT200000197A (es)
HR (1) HRP20000809A2 (es)
HU (1) HU224703B1 (es)
ID (1) ID28483A (es)
IL (1) IL139868A (es)
IS (1) IS2212B (es)
IT (1) IT1320120B1 (es)
JO (1) JO2298B1 (es)
MA (1) MA26754A1 (es)
MX (1) MXPA00011672A (es)
MY (1) MY127426A (es)
NO (1) NO317264B1 (es)
NZ (1) NZ508386A (es)
OA (1) OA11513A (es)
PA (1) PA8507201A1 (es)
PE (1) PE20010901A1 (es)
PL (1) PL195957B1 (es)
PT (1) PT1103545E (es)
SG (1) SG97171A1 (es)
SI (1) SI1103545T1 (es)
SK (1) SK285373B6 (es)
SV (1) SV2002000227A (es)
TN (1) TNSN00226A1 (es)
TR (1) TR200302077T4 (es)
UA (1) UA70326C2 (es)
UY (1) UY26458A1 (es)
YU (1) YU73400A (es)
ZA (1) ZA200006964B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050398A2 (en) 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
ES2226622T3 (es) * 1999-02-24 2005-04-01 F. Hoffmann-La Roche Ag Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
RS50932B (sr) * 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
EP1472377A2 (en) * 2002-01-31 2004-11-03 F. Hoffmann-La Roche Ag Genetic polymorphisms in the preprotachykinin gene
JP4490421B2 (ja) 2003-07-03 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 統合失調症を処置するデュアルｎｋ１／ｎｋ３アンタゴニスト
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
EP2281556A1 (en) 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Tablets with improved drugs substance dispersibility
BRPI0609699A2 (pt) 2005-03-23 2010-04-20 Hoffmann La Roche metabolitos para antatonistas de nk-1 para êmese
WO2007039420A1 (en) * 2005-09-23 2007-04-12 F. Hoffmann-La Roche Ag Novel dosage formulation
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
PE20151900A1 (es) 2013-03-15 2016-01-20 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
RU2673084C2 (ru) 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
WO2015120133A1 (en) 2014-02-07 2015-08-13 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT533280E (pt) * 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
KR100286412B1 (ko) * 1993-12-29 2001-04-16 더블유. 지. 콜 치환된 모르폴린 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW394773B (en) * 1995-03-24 2000-06-21 Takeda Chemical Industries Ltd Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
ES2226622T3 (es) * 1999-02-24 2005-04-01 F. Hoffmann-La Roche Ag Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
RS50932B (sr) * 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
PL195957B1 (pl) 2007-11-30
ATE253561T1 (de) 2003-11-15
BR0005616A (pt) 2001-07-17
AU775292B2 (en) 2004-07-29
GB2356863A (en) 2001-06-06
IS2212B (is) 2007-02-15
NZ508386A (en) 2003-02-28
CN1297888A (zh) 2001-06-06
EA004404B1 (ru) 2004-04-29
IL139868A (en) 2009-09-01
DE10058310A1 (de) 2001-05-31
CZ299286B6 (cs) 2008-06-04
SI1103545T1 (en) 2004-02-29
BRPI0005616B8 (pt) 2021-07-06
UY26458A1 (es) 2001-05-31
EA200001114A2 (ru) 2001-08-27
AU7178700A (en) 2001-05-31
BRPI0005616B1 (pt) 2017-12-12
AR033659A1 (es) 2004-01-07
MY127426A (en) 2006-11-30
EP1103545A1 (en) 2001-05-30
HU224703B1 (en) 2006-01-30
HK1036759A1 (en) 2002-01-18
ITMI20002575A1 (it) 2002-05-29
CZ20004399A3 (cs) 2001-07-11
HU0004725D0 (es) 2001-02-28
PL344147A1 (en) 2001-06-04
DK1103545T3 (da) 2004-03-15
ES2208205T3 (es) 2004-06-16
IL139868A0 (en) 2002-02-10
ID28483A (id) 2001-05-31
PE20010901A1 (es) 2001-09-20
SK17932000A3 (sk) 2001-11-06
CO5251405A1 (es) 2003-02-28
SK285373B6 (sk) 2006-12-07
SG97171A1 (en) 2003-07-18
NO317264B1 (no) 2004-09-27
DE60006340T2 (de) 2004-09-09
TNSN00226A1 (fr) 2002-05-30
CA2326529C (en) 2009-12-22
ZA200006964B (en) 2001-06-05
FR2801590A1 (fr) 2001-06-01
JO2298B1 (en) 2005-09-12
DOP2000000106A (es) 2002-07-30
BG64622B1 (bg) 2005-09-30
GB0028566D0 (en) 2001-01-10
EP1103545B1 (en) 2003-11-05
UA70326C2 (en) 2004-10-15
JP3480835B2 (ja) 2003-12-22
BG104992A (en) 2001-11-30
NO20006012L (no) 2001-05-30
MXPA00011672A (es) 2002-08-20
GT200000197A (es) 2002-05-22
HRP20000809A2 (en) 2001-12-31
IT1320120B1 (it) 2003-11-18
KR20010051983A (ko) 2001-06-25
DE60006340D1 (de) 2003-12-11
NO20006012D0 (no) 2000-11-28
PA8507201A1 (es) 2002-02-21
PT1103545E (pt) 2004-03-31
ES2171134A1 (es) 2002-08-16
JP2001151754A (ja) 2001-06-05
TR200302077T4 (tr) 2004-01-21
MA26754A1 (fr) 2004-12-20
OA11513A (fr) 2004-02-03
IS5725A (is) 2001-05-29
YU73400A (sh) 2003-02-28
KR100390117B1 (ko) 2003-07-04
CA2326529A1 (en) 2001-05-29
EA200001114A3 (ru) 2001-12-24
HUP0004725A2 (hu) 2002-04-29
GEP20022763B (en) 2002-08-26
GC0000151A (en) 2005-06-29
CN1152016C (zh) 2004-06-02

Similar Documents

Publication Publication Date Title
SV2002000227A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida caso 20502
EP1477482A4 (en) NEW PHENYLALANINE DERIVATIVE
ATE356119T1 (de) Pyrimidinone als melanin concentrating hormone receptor 1
PA8567001A1 (es) Composicion de ziprasidona y controles sinteticos
CO4970820A1 (es) Sal de bisulfato del inhibidor de la vih-proteasa
DE60009511D1 (de) Nematizide trifluorbutene
BR9902086A (pt) Formulações farmacêuticas.
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
MY129372A (en) Process to prepare oxazolidinones
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
SE9901077D0 (sv) Novel use
ATE240953T1 (de) Carbazolcarboxamide als 5-ht1f agonisten
SE9801494D0 (sv) Novel use
BR0016524A (pt) Suspensão compreendendo oxcarbazepina
DOP2002000371A (es) Fenil-heterociclil-eteres
DK0978284T3 (da) Anvendelse af 15-keto-prostaglandin-E-forbindelser som endothelinantagonister
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
BR0013292A (pt) Derivados de benzenamina como anti-coagulantes
DE69936052D1 (de) N1 modifizierte glycopeptide
GB0103045D0 (en) Organic Compounds
BR0009469A (pt) Tablete perfumado de detergente
DE60204882D1 (de) Zykloalkenylsulfonamidderivate
ATE321760T1 (de) N-aryl-2-oxazolidinone und deren derivate
ECSP003783A (es) 2-(3,5-bis-trifluorometil-fenil) -N-metil-N- (6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida